Therapy for recurrent malignant glioma in adults

Maciej Mrugala, Santosh Kesari, Naren Ramakrishna, Patrick Y. Wen

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Malignant gliomas are the most common form of primary brain tumors in adults. Although the prognosis remains poor, there has been recent progress in the treatment of these tumors. Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies.

Original languageEnglish (US)
Pages (from-to)759-782
Number of pages24
JournalExpert review of anticancer therapy
Volume4
Issue number5
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Glioma
Molecular Targeted Therapy
Angiogenesis Inhibitors
Brain Neoplasms
Genetic Therapy
Immunotherapy
Therapeutics
Neoplasms

Keywords

  • Angiogenesis
  • Chemotherapy
  • Gene therapy
  • Immunotherapy
  • Malignant glioma
  • Radiation therapy
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Therapy for recurrent malignant glioma in adults. / Mrugala, Maciej; Kesari, Santosh; Ramakrishna, Naren; Wen, Patrick Y.

In: Expert review of anticancer therapy, Vol. 4, No. 5, 01.01.2004, p. 759-782.

Research output: Contribution to journalReview article

Mrugala, Maciej ; Kesari, Santosh ; Ramakrishna, Naren ; Wen, Patrick Y. / Therapy for recurrent malignant glioma in adults. In: Expert review of anticancer therapy. 2004 ; Vol. 4, No. 5. pp. 759-782.
@article{5200ef0dd1aa44ef88583d3e5839e16f,
title = "Therapy for recurrent malignant glioma in adults",
abstract = "Malignant gliomas are the most common form of primary brain tumors in adults. Although the prognosis remains poor, there has been recent progress in the treatment of these tumors. Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies.",
keywords = "Angiogenesis, Chemotherapy, Gene therapy, Immunotherapy, Malignant glioma, Radiation therapy, Targeted molecular therapy",
author = "Maciej Mrugala and Santosh Kesari and Naren Ramakrishna and Wen, {Patrick Y.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1586/14737140.4.5.759",
language = "English (US)",
volume = "4",
pages = "759--782",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Therapy for recurrent malignant glioma in adults

AU - Mrugala, Maciej

AU - Kesari, Santosh

AU - Ramakrishna, Naren

AU - Wen, Patrick Y.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Malignant gliomas are the most common form of primary brain tumors in adults. Although the prognosis remains poor, there has been recent progress in the treatment of these tumors. Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies.

AB - Malignant gliomas are the most common form of primary brain tumors in adults. Although the prognosis remains poor, there has been recent progress in the treatment of these tumors. Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies.

KW - Angiogenesis

KW - Chemotherapy

KW - Gene therapy

KW - Immunotherapy

KW - Malignant glioma

KW - Radiation therapy

KW - Targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=5444269248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444269248&partnerID=8YFLogxK

U2 - 10.1586/14737140.4.5.759

DO - 10.1586/14737140.4.5.759

M3 - Review article

C2 - 15485312

AN - SCOPUS:5444269248

VL - 4

SP - 759

EP - 782

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -